


2016 Asian-Pacific Conference of Tumor Biology and Medicine
The 10th Forum of Chinese Middle-aged and Young Oncologist
The 11th Conference of Nanjing Molecular Biomarker and Nuclear Medicine
Targeted Theranostics
The second Forum of Zhong Shan Neuroendocrine Tumor Targeted Diagnosis
and Theranostics

November 25-27, 2016

(China · Nanjing)



Sponsor	Committee of Tumor Marker of Chinese Anti-cancer Association
	Nuclear Medicine Branch of Chinese Medical Association
	Neuroendocrine Tumor Branch of China Promotive Association for Medical and Health Care
Organizer	Committee of Tumor Marker of Jiangsu Anti-cancer Association
	Nuclear Medicine Branch of Jiangsu Medical Association
	Jiangsu Society of Biochemistry and Molecular Biology
	Nuclear Medicine Branch of Nanjing Medical Association
Co-organizer	The affiliated Nanjing Hospital of Nanjing Medical University
	Nanjing Clinical Nuclear Medicine Center

Welcome speech

Human cancer is an intrinsically heterogeneous disease which has become an overwhelming threat to human. Omics (genomics, proteomics, metabolomics) based big data has paved a way for precision medicine. Tumor biology is the king which underlies the basics of tumor occurrence, progression, and prognosis. The discovery of new molecular biomarkers is of great value for early diagnosis, molecular phenotyping and prognosis evaluation. Molecular imaging and nuclear medicine served as the bridge linking basic and clinical, has shown great potential in the clinical management.

“2016 Asian-Pacific Conference of Tumor Biology and Medicine” and “The 10th Forum of Chinese young and middle-aged and young oncologist”, “The 11th China Nanjing Conference of precision medicine-Molecular Biomarker and Nuclear Medicine Theranostics” and “The second Forum of ZhongShan Neuroendocrine Tumors” will be held from November 25 to 27 in Nanjing, China. It is sponsored by Committee of Tumor Marker of Chinese Anti-cancer Association and Chinese Society of Nuclear Medicine. The theme of conference is Precision test to Precision medicine.

The well-known specialists and scholars from different discipline including oncology, tumor biology, nuclear medicine and radiology, radiochemistry will make keynote lectures. Many experts and clinicians will attend the conference to share their experiences on genomics, proteomics, molecular imaging and radionuclide therapy. More than 300 attendees are estimated to attend the conference. The neuroendocrine tumor workshop and multi-disciplinary team (MDT) meeting will be held and shared. A CE credit will be awarded to all the attendees.

Nanjing is located in the southeast of China, which was the capital of Six Dynasties in ancient china. There are a variety of historical and cultural heritage and museums, which attracts many foreign visitors. The Zijin mountain villa is a very beautiful hotel, which has held several great conference such as the summit of European-China. Looking forward to meeting with you in the beautiful ancient city of Nanjing.



Chairman of the conference

The Conference Organization

Chairman:



Zhi-nan Chen Academician

Director of the Department of cell biology and cell engineering research center in the fourth military medical University of the PLA; Director of national key disciplines in cell biology; Executive director in Chinese anti-cancer Association, Chairman of the Professional Committee of tumor markers, Standing Committee of the Chinese Academy of engineering, Faculty of medicine and health.

Co-Chairman:



Prof. Yingdong Zhang

President of Nanjing Hospital Affiliated to Nanjing Medical University, Vice editor-in-Chief of 16 academic journals such as journal of Clinical Neurology.



Prof. Jianqiang Cai

Vice president of Cancer Institute & Hospital, Chinese Academy of Medical Sciences; Member of China medical doctor Association the Expert Committee; Vice-Chairman branch of soft tissue sarcoma of the China anti-cancer Association ; Vice Chairman of the Department of medicine, liver disease hepatitis intervention study group, Wu jieping Medical Foundation.



Prof. Yaming Li

Head & professor, department of nuclear medicine, the first affiliated hospital of China Medical University; the current society of nuclear medicine, Chinese Medical Association the Chairman of the National Committee; Vice Chairman of the Chinese nuclear society nuclear medicine branch; Vice President of Chinese society of nuclear medicine doctor Association; Deputy Editor-in-Chief of the Chinese Journal of nuclear medicine and molecular imaging

Executive Chairman:



Prof. Shukui Wang


Vice President of Nanjing Hospital Affiliated to Nanjing Medical University; Member of the Professional Committee of Jiangsu Province Association of cancer tumor markers; Member of Chinese anti-cancer Association; Vice Chairman of the medical laboratory science branch, Jiangsu Province

Secretary-general:



Prof. Ling Li

Professor, division of cell bioengineering Center in the Fourth Military Medical University; Member of anti-Cancer Association Committee; Member of cell engineering and transgenesis branch committee, Chinese Society for Cell Biology; Director of the institute of cell biology in shaanxi province.



Prof. Feng Wang

Director of department of the nuclear medicine in Nanjing Hospital Affiliated to Nanjing Medical University; Chairman of the medical society of nuclear medicine; Member of the China anti-cancer Association professional Committee of tumor markers

Secretary:



Yan Cao, Director
Nanjing Hospital affiliated to Nanjing Medical University

Chairman:

Zhi-nan Chen (Fourth Military Medical University)

Co-Chairman:

Ying-dong Zhang (Nanjing Hospital affiliated to Nanjing Medical University)

Jian-qiang Cai (Cancer hospital Chinese academy of medical science)

Ya-min Li (China Medical University affiliated First Hospital)

Executive Chairman:

Shu-kui Wang (Nanjing Hospital affiliated to Nanjing Medical University)

Secretary-general:

Ling Li (Fourth Military Medical University)

Feng Wang (Nanjing Hospital affiliated to Nanjing Medical University)

Secretary:

Yan Cao (Nanjing Hospital affiliated to Nanjing Medical University)

Conference schedule

1. Registration:

Date: November 25th, 2016 (Friday)

Address of the Conference hotel :

The Purple Palace Nanjing, 18 Huanling Road, Xuan Wu, Nanjing, China.

2. Schedule

2016-11-25 Pm 13:00~17:30

Session 1: The Second Forum of Zhong Shan Neuroendocrine Tumor

Moderators: Miao yi, The First Affiliated Hospital of Nanjing Medical University,
Chen jia, Jiangsu Cancer Hospital

1. 2016 ENETs annual meeting contents interpretation. (Jie Chen, The First Affiliated Hospital of Sun Yat-sen University)
2. Clinical pathological features and prognosis analysis of gastric neuroendocrine tumors in China. (Huang-Ying Tan, China-Japan Friendship Hospital)
3. Latest progress in imaging diagnosis of gastrointestinal pancreatic neuroendocrine tumor. (Li-Ming Jiang, Cancer Hospital, Chinese Academy of Medical Sciences)

Moderators: Yu Yan; Hong Zhu

4. The pathogenesis and metastasis of gastrointestinal neuroendocrine tumors expounded from the point of the pathology. (Jie Luo, China-Japan Friendship Hospital)
5. NETs surgical focus problems and challenges. (Hong Zhao, Cancer Hospital of the Chinese Academy of Medical Sciences)
6. Progress in surgical treatment and pathological features of pancreatic neuroendocrine tumor. (Jun-Li Wu, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province People's Hospital)

Debate: Which is preferred treatment strategy for unresectable G1-2 GEP – NENs, PRRT or chemotherapy

Moderators: Director Jia Chen; Bao-rui Liu

Experts: Xue-Xian Yan, Xiao-feng Sun, Zheng-yun Zhou, Jie Chen, Huang-ying Tan, Feng Wang, Hong Zhao, Lin Wang, Ji-rong Wang, Zheng-yun Zhou

2016-11-25 13:00~17:30 Parallel sessions2

Session 2: In vitro nuclear medicine labeled immunoassay meeting

Moderators: Zizheng Wang, Nanjing Hospital affiliated to Nanjing Medical University

Chen Yang, Suzhou Municipal Hospital

1. Detailed annotation of management in instruments, reagents and consumables. (Wen-wei Sun, China-Japan Union Hospital of Jilin University.)
2. Detailed annotation of methodological evaluation. (Yan-cai Wei, Suzhou Municipal Hospital)
3. Detailed annotation of quality assurance before analysis. (Li Zhu, Peking Union Medical College Hospital)
4. Detailed annotation of internal quality control. (Wei Qu, Nanjing Hospital affiliated to Nanjing Medical University)
5. Detailed annotation of quality assurance after analysis. (Yi-zhen Shi, The Second Affiliated Hospital of Soochow University)

2016-11-25 18:00 Welcome Ceremony

2016-11-25 20:00~21:00 The committee meeting of Nuclear Medicine Branch of Nanjing Medical Association.

2016-11-26 8:00~8:30 Opening Ceremony

Moderators: Shukui Wang, Nanjing Hospital affiliated to Nanjing Medical University

8:30~12:30: Keynote Speech

Plenary Session

Moderator: Yuetao Wang, The Changzhou People's Hospital

Lihua Bao, The First Affiliated. Hospital of Nanjing Medical University

1. The medical future of cancer molecular. (Zhi-nan Chen, Cell Engineering Research Center of The Fourth Military Medical University)
2. Progress of Lung Cancer Genomics. (Hong-bin Shen, Nanjing Medical University)
3. PET-MRI in the Diagnosis and Staging of Prostate Cancer. (Prof. A. Cahid Civelek, Johns Hopkins University)

Moderator: Minghua Du; Zhu Hong

4. Radiolabeled Peptides for Theranostics. (Prof. Hans-Jürgen Wester, Technical University of Munich)
5. PRRT: Current status and Perplexities. (Prof. XueXian Yan, Singapore General Hospital)

6. Development of Molecular probes for GRPR targeted imaging cancer. (Prof. Zhen Cheng, Stanford University)

12:30~13:30: Molecular imaging satellites

Moderator: Xu Chen; Cun-zhi Lu

13:30~18:00

Sessions 3: Nuclear Medicine and Theranostics

Moderator: Fang Li, Peking Union Medical College Hospital

JunTang, The Second Hospital Affiliated to Suzhou University

Shi-biao Sang, The First Hospital Affiliated to Suzhou University

1. Tumor targeting bacteria antitumor effect related with the tumor microenvironment and its mechanism of a preliminary study.(Zi-chuan Hua, Nanjing University)
2. State-of-the art of molecular probe for the diagnosis of Dementia (Ming-rong Zhang, National Institutes for Quantum and Radiological Science and Technology (NIRS-QST), Japan)
3. Clinical transformed scientific research - nuclide molecular imaging (Fang-Li, Peking Union Medical College Hospital)
4. Reconsideration of ^{18}F -FDG PET in the application of tumor. (Xiao-Feng Li, University of Louisville)
5. Nuclide imaging in the application of lung cancer radiation therapy. (Jin-chang Wu, The First Affiliated Hospital of Soochow University)
6. The latest progress in ^{68}Ga labeled drugs. (Jin Du, China Isotope & Radiation Corporation)

Moderator: Minghao Xie; Jiandong Bao

7. Development of molecular targeted therapies in Iodine refractory thyroid cancer. (Yan-song Lin, Peking Union Medical College Hospital)
8. The State-of-art of Optical imaging and application (Jing Wang, Xijing Hospital, the 4th Military Medical College)
9. The development and clinical study of ^{18}F -Al-labeled Peptide. (Min Yang, Jiangsu Institute of Nuclear Medicine)
10. To investigate the diagnostic value of ^{18}F -FDG PET in lung cancer. (Tian-nv Li, Jiangsu Province People's Hospital)
11. The latest progress in prostate cancer diagnosis and guide interpretation. (Rui-Peng Jia, Nanjing Hospital affiliated to Nanjing Medical University)

12. The value of radionuclide imaging in risk stratification of pulmonary embolism.
(Wei Fang, Fuwai Hospital)

13:30~18:00 Sessions 4:

Moderator: Shukui Wang, Nanjing First Hospital, Nanjing Medical University

Chen Yang, Suzhou Municipal Hospital

From Precision Signature Assay to Precision Medicine

1. Appropriate individualized tumor diagnosis technology and its application. (Qishui- Ou, The First Affiliated Hospital of Fujian Medical University)
2. Myeloproliferative neoplasms caused Cardio-cerebral vascular diseases and their detection strategy. (Ming Guan, Huashan Hospital Affiliated to Fudan University)
3. The development of 3D microfluidic tumor cell/tissue arrays (3D μ FC/TA) chip drug susceptibility test system. (Fen-yong Sun, Shanghai Tenth People's Hospital Affiliated to Tongji University)
4. Tumor markers for diagnostic reagents in research and industrial transformation. (Biao Huang, Jiangsu Institute of Nuclear Medicine)
5. Decade of deliberate thinking about photodynamic therapy for tumor. (She-gan Gao, The First Affiliated Hospital of Henan Science and Technology University)
6. Mutations in tumor mitochondrial genome evolution mode analysis and biological significance. (Jin-liang Xing, Teaching and Experiment Center of Basic Medicine of the Fourth Military Medical University)

12:00~13:30 Kick-off meeting for multi-center clinical research in ^{68}Ga -PSMA-11 PET for the diagnosis of preoperative staging of prostate cancer.

Moderator: Rui-peng Jia; Feng Wang

Abstract Submission

If you are a physician, scientist, technologist, lab professional, or educator/course director in the field of oncology, nuclear medicine and molecular imaging, Radiology, Laboratory medicine. This Meeting provides you the ideal platform to present your research to a global audience of your peers, while increasing your professional recognition in the field. Manuscript submissions are welcome for the scientific tracks related with tumor research and clinical studies.

1.1 Oncobiology

1.Tumor biomarkers and proteomics; 2. Virus and tumor; 3.Tumor genomics ; 4. Tumor cell apoptosis and cell differentiation; 5.Tumor cell cycle regulation and signal transduction; 6.The extracellular matrix of the tumor and metastasis; 7.Inflammatory-carcinoma chain and tumor processing 8.Tumor multidrug resistance and reversal; 9.Tumor bioinformatics; 10.DNA damage and repair of tumor; 11.Metabolism of tumor cells; 12.New target of tumor and related drug design; 13. Tumor stem cell.

1.2 Molecular Medicine

1.Molecular diagnosis; 2.Molecular imaging; 3.Personalized therapy; 4.New molecular medicine technique; 5.Personal risk assessment and early detection based on gene; 6. Molecular intervention; 7.Gene detection and Pharmaceutical therapeutic effect.

1.3 Nuclear Medicine

1.Nuclear medicine imaging; 2.Theranostics; 3.Experimental nuclear medicine; 4.In vitro analysis by nuclear medicine; 5.Radiopharmacology; 6.Nuclear medicine construction and interdisciplinary research.

1.4 Clinical Oncology and Medicine

1.Tumor targeted therapy; 2.Biological treatment of tumor and tumor immunity; 3.Molecular nuclear medicine and diagnostic and therapy of tumor; 4.The clinical tumor proteomics; 5.Tumor biological chip; 6.Tumor vaccine; 7. New tumor marker research; 8.Tumor vascular targeting and its imaging; 9.The tumor prognosis and prediction; 10.Tumor traditional medicine and therapy.

Submission Requirement

2.1 Unpublished manuscript is currently being accepted for the Meeting in Nanjing, China and the deadline is October 30th, 2016. The total number of words in the abstract is no more than 300, which should consists of aim, methods, results and conclusion(s), your name, department and your zipcode. All abstracts will be compiled in the Paper Compilation. Please note“2016 Asian-Pacific Conference of Tumor Biology and Medicine” on the cover of envelope.

2.2 Methods of submission

2.2.1 Email: apctbm@126.com

2.2.2 Post: Xue Xue, Nanjing Hospital affiliated to Nanjing Medical University ,No.68, Changle Rd, Nanjing, China, 210006

2.2.3 Online registration: [http:// www.njcnmc.com/](http://www.njcnmc.com/) or download the registration form, fill in the blanks and send it to email: apctbm@126.com.



2.2.4 Deadline of submission: Oct 30th, 2016.

2.2.5 Notification : The notification of the reviewed manuscript/abstract will be sent out in early October.

Registration Fee

Participant	Before November 1st	After November 1st	Accommodation (per day)
Domestic	RMB 1000/person	RMB 1200/person	single/standard room: RMB 440
Students	RMB 300/person	RMB 400/person	single/standard room: RMB 440
Foreign	\$ 400/person	\$ 500/person	single/standard room: RMB 440

Contact and Registration

1. Contact:

Xue Xue: Nanjing Hospital affiliated to Nanjing Medical University (postcode: 210006)

Tel: 86-25-84685034 Mobile: 86-13739197036

Yang Yu: Tel: 86-25-84685032 Mobile: 86-13770623640

2. Registration:

Date: November 25th, 2016 (Friday)

Address of the Conference hotel :

The Purple Palace Nanjing, 18 Huanling Road, Xuan Wu, Nanjing, China.

3. Registration Forms

Official Website: <http://www.njcnmc.com/>

Email: apctbm@126.com

4. Attendee registration receipt

2016 Asian-Pacific Conference of Tumor Biology and Medicine
The 10th Forum of Chinese middle-aged and young oncologist
The 11th China Nanjing Conference of Molecular Biomarker and Nuclear
Medicine Targeted Theranostic
The second Forum of ZhongShan Neuroendocrine Tumors

Name	Gender	Department	Post code	Tel	Email	Accommodation or not